MASIMO Q2 Results Top Expectations
August 10, 2022
Trending News ☀️
Masimo ($NASDAQ:MASI) released their Q2 results today, and they topped expectations. Non-GAAP EPS came in at $1.35, beating estimates by $0.15. Revenue was $565.3M, beating estimates by $24.74M. This is great news for Masimo, and investors will likely be pleased with the results. This should have a positive impact on Masimo’s market share and earnings in the long term.
The release of MASIMO’s Q2 results topped expectations, with the stock opening at $153.3 and closing at $148.2. Media sentiment was mostly mixed, with some praising the results and others expressing skepticism.
Based on VI’s Risk Rating, MASIMO is a high risk investment in terms of financial and business aspects.
However, the company’s strong fundamentals reflect its long term potential. For more information on what areas present potential risks, please visit our website.
MASIMO Corp.oration is a medical technology company that develops, manufactures, and markets a range of patient monitoring products. The company’s products include pulse oximeters, sensors, and other related accessories. The mixed news wasn’t enough to keep investors excited about the stock, as the company’s guidance for the full year was largely in line with analysts’ expectations.
Leave a Comment